Skip to content
Tenfell
Awarded contract
Published 29 Mar 2024

Fibrinogen concentrate used for congenital afibrinogenaemia and dysfibrinogenaemia

Irish Blood Transfusion Service · Ireland

Key facts

Awarded
02 Jan 2024
Contract starts
02 Jan 2024
Procedure
Open procedure
Buyer type
Other public body

Awarded to

SupplierValue
Octapharma AG—

Description

Human fibrinogen concentrate is used for congenital afibrinogenaemia and dysfibrinogenaemia states for treatment of bleeding complications. It is also used in acquired hypofibrinogenemia conditions such as massive haemorrhage, acquired coagulopathy, liver disease with bleeding and in obstetric haemorrhage. The product should be licensed for these clinical indications and approved by the HPRA. Fibrinogen, in presence of thrombin, activates FVIII and calcium, which is necessary to convert fibrinogen into stable three-dimensional fibrin coagula. The IBTS is responsible for the distribution of fibrinogen to users nationwide. IBTS must therefore have a sufficient stock and a stable supply of fibrinogen concentrates to meet patient needs.

Categories (CPV)

Similar open tenders

About Irish Blood Transfusion Service

Their tenders, awards, contracts coming up for renewal, decision makers and committee papers.

View buyer profile

Their other open tenders

Published by the buyer on TED (Tenders Electronic Daily) (EU open data (Decision 2011/833/EU)). Always read the original notice before responding.